$OGEN· SEC filing ·

OGEN Doses First Patient in Phase IIa ONP-002 Trial for Concussion, Mackay Hospital Activated March 31, 2026, 40-Patient Study, $9B Global Concussion Market, Intranasal Delivery, CEO Janet Huffman, Dr. James Kelly, HREC Approval, Targets Q4 2026 IND Submission

Oragenics Inc. · Now $0.61

Post-detection moves

1h
1d
3d
7d
30d

Get alerts like this in real time

Push notifications the moment a signal fires. No spam, no crypto, no fluff.

Download for iOS